Rokit Healthcare Sees 118% Surge in Q1 Sales... Reports 2.35 Billion Won Operating Loss

First Quarter Sales Reach 8 Billion Won

Overseas Expansion in the US and Other Markets Drives Growth

Continued Global Clinical and R&D Investment

Profitability Remains in the Red

Rokit Healthcare announced on May 15th that it recorded consolidated sales of 8.05 billion won in the first quarter of this year. This represents a 118% increase compared to the 3.69 billion won recorded during the same period last year.

Rokit Healthcare company logo image. Rokit Healthcare

The company explained that sales growth was driven by the expansion of domestic and international business, strengthening its response to overseas markets, and diversifying its sales portfolio. Rokit Healthcare added that it is expanding its business foundation, focusing on overseas markets such as the United States and the Middle East.

However, the company posted an operating loss of 2.35 billion won. Rokit Healthcare stated that costs were incurred due to the global clinical expansion of the AI cartilage regeneration platform, research on the domestic AI diabetic foot regeneration platform, development of the AI kidney prediction and diagnosis platform, compliance with global regulations, and the advancement of its AI-based digital healthcare platform. The company emphasized that it is prioritizing the global commercialization of its AI-based organ regeneration platform and the accumulation of clinical data over short-term profitability.

A Rokit Healthcare representative stated, "Despite the off-season in the first quarter, we achieved more than double the sales growth compared to the same period last year," and added, "We plan to focus on establishing the global standard for our AI-based organ regeneration platform and accumulating clinical data."

This content was produced with the assistance of AI translation services.